Trusted Resource for Clinical Trials, Protocols & Progress
Bridging Studies as a Part of Phase 3 Programs: Regulatory Role, Design, and Global Development How Bridging Studies Integrate Local Data into Global Phase 3 Clinical Development What Are Bridging Studies in Clinical Research? A bridging study is a supplemental clinical study that provides data on the efficacy, safety, dosage, or pharmacokinetics (PK) of a…
Post-Trial Access and Continuation in Phase 2 Patients Ensuring Post-Trial Access and Continuity of Care for Phase 2 Clinical Trial Participants Introduction As investigational drugs advance through development, questions about continued access for participants after a Phase 2 study ends become increasingly important. Post-trial access (PTA) refers to the provision of a study drug or…
Read More “Post-Trial Access and Continuation in Phase 2 Patients” »
Comparative Effectiveness Research in Phase 4: Generating Real-World Value How to Conduct Comparative Effectiveness Research in Phase 4 Clinical Trials Introduction Once a drug is approved and enters the real world, the next question stakeholders ask is: “How does this treatment compare to others already in use?” That’s the domain of Comparative Effectiveness Research (CER),…
Read More “Comparative Effectiveness Research in Phase 4: Generating Real-World Value” »
Clinical Pharmacology Reviewer Expectations for Phase 1 Data What Regulatory Reviewers Look For in Early Clinical Pharmacology Packages Introduction Phase 1 clinical studies form the backbone of early drug development. These studies not only establish safety and tolerability but also generate the essential clinical pharmacology data that regulatory reviewers rely on to evaluate future clinical…
Read More “Clinical Pharmacology Reviewer Expectations for Phase 1 Data” »
Pharmacoeconomic Evaluations Embedded in Phase 3 Trials: Building the Value Case Alongside Clinical Evidence How Pharmacoeconomic Studies in Phase 3 Trials Support Drug Value and Market Access What Is Pharmacoeconomic Evaluation? Pharmacoeconomic (PE) evaluation involves the analysis of cost versus benefit of a drug or intervention. These evaluations help determine whether a therapy delivers value…
Managing Placebo Use When Standard-of-Care Exists in Phase 2 Trials Ethical and Strategic Approaches to Placebo Use in Phase 2 Trials with Existing Standard-of-Care Introduction Phase 2 trials are designed to evaluate the efficacy and safety of investigational treatments before proceeding to large-scale confirmatory trials. While placebo-controlled designs are the gold standard for assessing efficacy,…
Read More “Managing Placebo Use When Standard-of-Care Exists in Phase 2 Trials” »
Using Real-World Evidence (RWE) Platforms to Streamline Phase 4 Studies How Real-World Evidence Platforms Accelerate and Optimize Phase 4 Clinical Trials Introduction As Phase 4 trials move beyond the confines of tightly controlled environments, the ability to collect, analyze, and interpret real-world data (RWD) becomes central to post-marketing success. Real-World Evidence (RWE) platforms are digital…
Read More “Using Real-World Evidence (RWE) Platforms to Streamline Phase 4 Studies” »
Trial Master File (TMF) Readiness in Phase 1: What to Include Early On Ensuring TMF Readiness from the Start of Phase 1 Clinical Trials Introduction While often associated with large-scale Phase 3 trials, the Trial Master File (TMF) is just as critical during Phase 1. Regulatory agencies expect complete, current, and accessible documentation—even in early…
Read More “Trial Master File (TMF) Readiness in Phase 1: What to Include Early On” »
Lessons from Failed Phase 3 Trials: What Went Wrong and How to Avoid It Analyzing Why Phase 3 Clinical Trials Fail and What We Can Learn from Them Why Learning from Failure Is Essential Phase 3 clinical trials are often seen as the final hurdle before a drug can be submitted for regulatory approval. Yet,…
Read More “Lessons from Failed Phase 3 Trials: What Went Wrong and How to Avoid It” »
Ethical Considerations in Experimental Phase 2 Designs Managing Ethics in Innovative and High-Risk Phase 2 Clinical Trial Designs Introduction Phase 2 trials are increasingly adopting adaptive, biomarker-driven, and accelerated models to streamline drug development. While these innovative designs offer scientific and operational advantages, they also present unique ethical challenges, particularly in patient selection, consent, risk…
Read More “Ethical Considerations in Experimental Phase 2 Designs” »
